AI English summary of an SEC filing — figures as filed
AbbVie ABBVAbbVie said worldwide net revenues for the Q3 2026 quarter were $17.404 billion, up 10.3% on a reported basis and 10.5% on an operational basis.
Key points
AI summaryAbbVie said worldwide net revenues for the Q3 2026 quarter were $17.404 billion, up 10.3% on a reported basis and 10.5% on an operational basis.
The company said immunology portfolio net revenues in Q3 were $9.165 billion, up 16.3% on a reported basis, with Skyrizi at $5.776 billion, Rinvoq at $2.706 billion and Humira at $683 million.
AbbVie said diluted earnings per share for Q3 were $2.37 on a GAAP basis and $3.82 on an adjusted basis, and included an unfavorable impact of $0.11 per share related to acquired IPR&D and milestones expense.
AbbVie said it is raising its adjusted diluted EPS guidance for full-year 2026 to $13.76 to $13.96 from $13.95 to $13.99, and said it is increasing its quarterly cash dividend from $1.73 to $1.82 per share.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
AbbVie Q3 net revenues $17.404 billion
AbbVie said worldwide net revenues for the Q3 2026 quarter were $17.404 billion, up 10.3% on a reported basis and 10.5% on an operational basis.
Source · Based on the filing body and exhibits
Immunology and Skyrizi and Rinvoq sales
The company said immunology portfolio net revenues in Q3 were $9.165 billion, up 16.3% on a reported basis, with Skyrizi at $5.776 billion, Rinvoq at $2.706 billion and Humira at $683 million.
Source · Based on the filing body and exhibits
Q3 EPS and acquired IPR&D impact
AbbVie said diluted earnings per share for Q3 were $2.37 on a GAAP basis and $3.82 on an adjusted basis, and included an unfavorable impact of $0.11 per share related to acquired IPR&D and milestones expense.
Source · Based on the filing body and exhibits
Adjusted EPS outlook raised, dividend increased
AbbVie said it is raising its adjusted diluted EPS guidance for full-year 2026 to $13.76 to $13.96 from $13.95 to $13.99, and said it is increasing its quarterly cash dividend from $1.73 to $1.82 per share.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…